What is peptide therapy?

A marketing umbrella for clinics and telehealth services prescribing or administering peptides, most often growth-hormone secretagogues (sermorelin, ipamorelin, CJC-1295) and BPC-157, for goals like recovery, body composition and anti-aging. It is not a defined medical specialty, and the term covers everything from on-label prescribing to compounded off-label use.

Is peptide therapy FDA-approved?

Some specific peptides are FDA-approved for specific indications (tesamorelin for HIV-associated visceral fat, GLP-1 drugs for diabetes and weight). Most peptides used in therapy clinics are not approved for the goals they are marketed for and are compounded, a route the FDA restricted further in 2023 for several popular peptides including BPC-157. 'Peptide therapy' as a category is not an approved treatment.

Is peptide therapy safe?

It depends entirely on which peptide, which source, and which clinician. An on-label prescription from a licensed clinician is ordinary medicine. Compounded or research-channel peptides for unproven uses carry the risks of limited safety data plus, outside a regulated pharmacy, unverified quality. The honest summary is that much of peptide therapy runs ahead of its safety evidence.

Does peptide therapy actually work?

For approved peptides used on-label, yes, for their approved purpose. For the recovery, body-composition and anti-aging goals most peptide therapy targets with GH secretagogues and BPC-157, the human outcome evidence is largely missing, even where the mechanism is plausible. We grade each compound's actual evidence individually.

Why did the FDA restrict BPC-157?

In 2023 the FDA placed BPC-157 (and several other peptides) in a category that effectively bars routine pharmacy compounding, citing insufficient characterization and safety data. That is the central regulatory fact about much of the peptide therapy field: a compound at the center of it cannot be routinely compounded under current guidance. See our BPC-157 review and research-use-only explainer.

Compound profile· Regulation

Peptide therapy, separated from the marketing

By The PepVise Editorial Team · Reviewed June 4, 2026 · 11 min read

Wellness clinics offer peptide therapy for recovery, anti-aging and fat loss. What the term actually covers, which peptides are FDA-approved for what, and the regulatory grey zone most of it lives in.

We describe what has been measured — by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.

— The PepVise Editorial Teamfrom the house style guide

Methodology

How we read the literature

Evidence tier: We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage: Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status: We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain: Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.

Frequently asked

The questions readers actually bring us.

What is peptide therapy?: A marketing umbrella for clinics and telehealth services prescribing or administering peptides, most often growth-hormone secretagogues (sermorelin, ipamorelin, CJC-1295) and BPC-157, for goals like recovery, body composition and anti-aging. It is not a defined medical specialty, and the term covers everything from on-label prescribing to compounded off-label use.
Is peptide therapy FDA-approved?: Some specific peptides are FDA-approved for specific indications (tesamorelin for HIV-associated visceral fat, GLP-1 drugs for diabetes and weight). Most peptides used in therapy clinics are not approved for the goals they are marketed for and are compounded, a route the FDA restricted further in 2023 for several popular peptides including BPC-157. 'Peptide therapy' as a category is not an approved treatment.
Is peptide therapy safe?: It depends entirely on which peptide, which source, and which clinician. An on-label prescription from a licensed clinician is ordinary medicine. Compounded or research-channel peptides for unproven uses carry the risks of limited safety data plus, outside a regulated pharmacy, unverified quality. The honest summary is that much of peptide therapy runs ahead of its safety evidence.
Does peptide therapy actually work?: For approved peptides used on-label, yes, for their approved purpose. For the recovery, body-composition and anti-aging goals most peptide therapy targets with GH secretagogues and BPC-157, the human outcome evidence is largely missing, even where the mechanism is plausible. We grade each compound's actual evidence individually.
Why did the FDA restrict BPC-157?: In 2023 the FDA placed BPC-157 (and several other peptides) in a category that effectively bars routine pharmacy compounding, citing insufficient characterization and safety data. That is the central regulatory fact about much of the peptide therapy field: a compound at the center of it cannot be routinely compounded under current guidance. See our BPC-157 review and research-use-only explainer.

What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action — approval, restriction, or a class warning — would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Regulation · Compound profile

"Research Use Only", What It Actually Means

FDA's position on research-use-only labeling, the 503A/503B distinction, the 2023 enforcement actions, and what this framing means for buyers.

12 min read

Regulation · Explainer

Where to Buy Peptides, The Taxonomy of Vendors

Research-chemical suppliers versus compounding pharmacies versus underground sellers, the legal framework and red flags. No vendor directory.

14 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.